ABL Bio (CEO Lee Sang-hoon) participated in ‘BIO KOREA 5’ held at COEX, Seoul for three days from May 10th (Wednesday) to coming 12th (Friday).
ABL Bio is a bio-venture company that has developed an innovative bispecific antibody platform and pipeline for immuno-oncology and neurodegenerative diseases. Previously, in the field of degenerative brain disease, it succeeded in developing the platform ‘Grabbody-B’ with increased permeability of the blood-brain barrier, drawing attention from the industry.
In addition, based on this, it is researching a pipeline targeting Parkinson’s disease treatment ‘ABL301’ and central nervous system diseases, and signed a technology transfer contract with Sanofi, a global pharmaceutical company, in January of last year.
In the field of immuno-oncology, ‘4-1BB’-based bispecific antibody platform ‘Grabbody-T’, whose efficacy and safety have been confirmed, and pipelines ‘ABL503’, ‘ABL111’, ‘ABL101’, ‘ABL105’, ‘ABL103’ to which it is applied, etc. is developing It is known that these pipelines are already undergoing global clinical trials in the US, China, and Korea, or are preparing to enter clinical trials.
In addition to this, the company explains that it is actively conducting research and development on a number of non-clinical pipelines, including ‘ABL102’ and ‘ABL602’.
At this exhibition, ABL Bio will showcase a number of immuno-oncology drugs, including ‘ABL2’, which is currently in phase 3 and 001 clinical trials in the US, and based on its bispecific antibody technology, it will be used as antibody drug conjugate (ADC) and central nervous system (CNS) treatment. Introduced pipeline expansion plans.
ABL Bio said, “As the interest and participation of leading domestic and foreign companies in Bio Korea has increased over the years, we came here expecting it to be an opportunity for active communication.” We are making every effort so that the vision pursued by the exhibition can be delivered to all visitors to the exhibition.”
Meanwhile, ‘BIO KOREA 18’, which celebrated its 2023th this year, was hosted by the Korea Health Industry Development Institute and Chungcheongbuk-do. Since 2006, BIO KOREA, which has been striving to promote the global status and continuous growth of the Korean health industry, has been strengthening its position as Korea’s representative bio-health international convention with world-renowned scholars and business experts participating every year. BIO KOREA 2023, together with domestic and foreign companies related to the health industry such as bio, pharmaceuticals, medical devices, cosmetics, and food, as well as companies and institutions of interest such as consulting, academia, and related organizations, offers various programs such as conferences, business partnering, exhibitions, and invest fairs. It goes on.